Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $-0.73 · Revenue $83.94M · 9 analysts
Est. EPS $-0.71 · Revenue $98.06M · 9 analysts
Est. EPS $-3.01 · Revenue $312.75M · 11 analysts
Est. EPS $-0.62 · Revenue $101.35M · 6 analysts
EPS $-0.81 · Revenue $32.70M
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $189.8M | +45.8% | +18.5% |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-196.5M | +24.6% | +11.4% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | +89.7% | +0.0% | -0.7% |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | -101.2% | +50.4% | +21.8% |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | -103.6% | +48.3% | +25.3% |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-116.6M | -2.4% | -20.7% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | -61.5% | +29.8% | -1.8% |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 1.5% | -38.2% | +4.9% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 4.41x | +36.1% | -17.2% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $480.2M | +22.4% | -1.1% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -3.11 vs -3.17 | +2.0% | -0.73 vs -0.81 | +9.6% |
| Revenue Surprise | $189.8M vs $189.0M | +0.4% | $71.3M vs $67.7M | +5.3% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Aug 31, 2026 | Smith Hunter C | officer: Chief Financial Officer | Common Stock | A | 57,187 | $25.79 |
| Aug 31, 2026 | Smith Hunter C | officer: Chief Financial Officer | Common Stock | D | 23,072 | $104.59 |
| Aug 31, 2026 | Smith Hunter C | officer: Chief Financial Officer | Common Stock | D | 11,514 | $105.37 |
| Aug 31, 2026 | Smith Hunter C | officer: Chief Financial Officer | Common Stock | D | 28,188 | $106.20 |
| Aug 31, 2026 | Smith Hunter C | officer: Chief Financial Officer | Employee Stock Option (Right to Buy) | D | 57,187 | $25.79 |
Operator: Good day, and thank you for standing by. Welcome to the Rhythm Pharmaceuticals Second Quarter 2026 Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Dave Connolly, Investor Relations at Rhythm Pharmaceuticals. Please go ahead. David Connolly: Thank you, Didi. I'm Dave Connolly here at Rhythm Pharmaceuticals. For those of you participating on the conference call, our slides can be accessed and controlled by going to the Investors section of our website, ir.rhythmtx.com. This morning, we issued our press release that provides our Q2 2026 financial results and a business update, and that press release is available on our website. We also released data for RM-718's Phase II trial in acquired hypothalamic obesity. Our agenda today is listed on Slide 2. On the call are David Meeker, our Chairman, Chief Executive Officer and President; Jennifer Lee, Executive Vice President, Head of North America; Hunter Smith, Chief Financial Officer; and Yann Mazabraud, Executive Vice President, Head of International is on the line joining us from Europe. On Slide 3, I'll remind you this call contains remarks concerning future expectations, plans and prospects, which constitute forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in our most recent annual or quarterly reports on file with the SEC. In addition, any forward-looking statements represent our views as of today and should not be relied upon as representing our views as of any subsequent dates. We specifically disclaim any obligation to update such statements. With that, I'll turn the call over to David Meeker, who will begin on Slide 5. David Meeker: Good morning, and thank you for joining us. We have a lot to share today, headlined by a strong start to the U.S. launch of IMCIVREE for acquired hypothalamic obesity, reinforcing our conviction that HO represents a meaningful long-term opportunity for Rhythm. Progress during the quarter wasn't limited to our commercial business. In June, we presented positive 6-month data in Prader-Willi at ENDO showing setmelanotide achieved clinically meaningful BMI and BMI-Z score reductions, reductions in fat mass and preservation of lean mass and improvements in hyperphagia and anxiety measures. These data confirm the mechanistic rationale that MC4R agonism plays a key role in the pathology of PWS and demonstrated the positive impact IMCIVREE can have in this difficult-to-treat patient population. We look forward to updating you on the path forward for PWS in the next few months. Which brings us to our pipeline. We believe our next-generation MC4R agonists have the potential to bring meaningful new treatment options to patients living with rare neuroendocrine diseases. And today, we announced …
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
David Meeker | Chairman, President & Chief Executive Officer | USD 1,581,180 | — | 1954 | Active |
Yann Mazabraud | Executive Vice President & Head of International | USD 972,148 | Male | 1973 | Active |
Hunter C. Smith | Chief Financial Officer & Treasurer | USD 892,477 | Male | 1969 | Active |
Jennifer Lee | Executive Vice President & Head of North America | USD 838,635 | Female | 1975 | Active |
Alastair Garfield | Chief Scientific Officer | USD 806,385 | — | 1980 | Active |
Joseph Shulman | Chief Technical Officer | USD 734,854 | Male | 1975 | Active |
Jim Flaherty | Senior Vice President & General Counsel | — | Male | — | Active |
Sarah Ryan | Vice President of Sales & Marketing | — | Female | — | Active |
Christopher German | Corporate Controller & Principal Accounting Officer | — | Male | 1972 | Active |
David Connolly | Head of Investor Relations & Corporate Communications | — | Male | — | Active |
NVIDIA's blockbuster earnings sent shockwaves through tech on Thursday, but Wall Street analysts were busy reshaping the landscape elsewhere, issuing a flurry of upgrades, downgrades, and fresh initiations across energy, crypto infrastructure, banking, and biotech.
Bank of New York Mellon Corp acquired a new position in Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 394,044 shares of the company's stock, valued at approximately $43,751,000. Bank of New York Mellon Corp owned
Duquesne Family Office has beefed up its healthcare holdings.
-- Approximately 5,000 to 8,000 patients estimated to be living with acquired HO in Japan -- -- Commercial launch in Japan expected by end of 2026, pending final pricing determination --
Rhythm Pharmaceuticals develops medicines for rare forms of obesity. The company has little competition in its target market.
